Tumor immunotherapy using EBV-specific cytotoxic T lymphocytes (CTLs) has been successful for the treatment of EBV-associated lymphomas arising in the immunocompetent host. However, the majority of referred patients have EBV-negative lymphomas, precluding the use of virus-targeted T cells;also, CTLs do not eliminate tumors in all patients, likely because potentially immunogenic tumors arising in immunocompetent persons develop immune evasion strategies that subvert the effector function of the infused CTLs. These include downregulation of viral antigens, and the production of soluble immunomodulatory cytokines, such as 1L4, from malignant and infiltrating inhibitory cells, which limit the in vivo activity of adoptively transferred T cells. To extend T cell therapy to all patients with Hodgkin lymphoma (HL), regardless of tumor EBV status, we used the previous SPORE funding cycle to develop a strategy to reactivate and expand CTLs with specificity for the nonviral tumor-associated antigens (TAAs) Survivin SSX2, MAGE-A4, NY-ESO-1 and FRAME expressed by malignant cells. We reasoned that targeting multiple TAAs simultaneously would minimize tumor immune escape and therefore are assessing the safety and efficacy of these multiTAA-CTLs in vivo. We now propose, in Project 1, to address two remaining barriers to successful T cell therapy, namely (a) low target antigen expression, and (b) the immunosuppressive tumor microenvironment. Thus, our central hypotheses are that the efficacy ot immunotherapy for HL can be enhanced by combination with epigenetic drugs and by modifying infused T cells to retain Thi function in the Th2 cytokine milieu of the tumor. Hence, in Aim 1 of our renewal application, in a phase I clinical trial, we will generate and infuse multiTAA-targeted CTLs in combination with a hypomethylating agent known to upregulate T cell target antigen expression on malignant cells and sensitize them to immune-mediated destruction. The impact of this combination therapy on tumor immunogenicity, T cell antitumor activity and epitope spreading will be assessed in Aim 2. Finally, Aim 3 seeks to protect adoptively transferred multiTAA-targeted CTLs from the tumor microenvironment by engineering the T cells to express a chimeric cytokine receptor that can bind the Th2 cytokine 1L4 and convert its inhibitory signal to one that is activating. Although restricted to preclinical models initially.
Aim 3 will be clinically developed in the future. In summary, this approach combining drug therapy with tumorspecific CTLs may enable T cell immunotherapy to become more broadly applied to all patients with cancer.
We have developed a personalized medicine to treat Hodgkin's lymphoma (HL) by taking immune cells (T cells) from patient blood, and training them to kill HL cells. These cells will then be administered with a drug which improves their ability to recognize the tumor. Finally we will protect the T cells from the inhibitory tumor environment by modifying them with a molecule that delivers a potent activating signal at the tumor site. We believe that this novel approach will be safe and effective for HL and ultimately for other cancers.
|Rouce, Rayne H; Heslop, Helen E (2016) Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov 6:579-80|
|Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-34|
|Bollard, Catherine M; Heslop, Helen E (2016) T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127:3331-40|
|Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2016) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol :|
|Ramos, Carlos A; Heslop, Helen E; Brenner, Malcolm K (2016) CAR-T Cell Therapy for Lymphoma. Annu Rev Med 67:165-83|
|Ramos, Carlos A; Savoldo, Barbara; Torrano, Vicky et al. (2016) Clinical responses with T lymphocytes targeting malignancy-associated Îº light chains. J Clin Invest 126:2588-96|
|Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81|
|Zhou, Xiaoou; Naik, Swati; Dakhova, Olga et al. (2016) Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther 24:823-31|
|Eckstein, Olive S; Wang, Linghua; Punia, Jyotinder N et al. (2016) Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44:740-4|
|Naik, Swati; Nicholas, Sarah K; Martinez, Caridad A et al. (2016) Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137:1498-1505.e1|
Showing the most recent 10 out of 218 publications